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scription are still unknown. However,
upregulation of Pax gene expression is
clearly involved in rhabdomyosarcoma-
genesis. Pax3 is known to regulate c-met
gene transcription, overexpression of
which is occasionally seen in human
RMS. Overexpression of HGF/SF in
transgenic mice also caused RMS to
develop in 4% of mice (Merlino and
Helman, 1999). More recently, RMS is
frequently observed in mice carrying
overexpression of HGF/SF gene in an
Ink4a/Arf null background (Sharp et al.,
2002). These reports strongly suggest
that rhabdomyosaromagenesis impli-
cates Fos, Pax, c-met, and HGF/SF sig-
naling pathways. Although the origin of
RMS cells is assumed to be from myo-
genic cells such as satellite cells, recent
work demonstrates existence of novel
stem cells in muscle, which give rise to
myogenic cells during muscle regenera-
tion (Asakura et al., 2002; Polesskaya et
al., 2003).Therefore, the novel stem cells
in muscle such as side population (SP)
cells may be a developmental origin for
RMS cells, in which Fos/Pax/c-met path-
way is involved. In the near future, finding
the molecular mechanisms of Fos/Pax/c-
met pathway involved in rhabdomyosar-
comagenesis and the developmental
origin of RMS would not only facilitate
our understanding of the mechanisms of
rhabdomyosarcomagenesis but also
develop novel therapeutic applications
for human RMS patients.
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P R E V I E W S
The accumulation of individual proteins
within eukaryotic cells reflects a tightly
controlled balance between protein syn-
thesis and degradation. Two major path-
ways for the degradation of proteins have
been described: cytosolic degradation by
the proteasome and autophagic degra-
dation of proteins and organelles within
the lysosome (Klionsky and Emr, 2000).
Considerable evidence suggests that the
proteasome is responsible for the regu-
lated degradation of short-lived proteins
involved in cell cycle control as well as
proteins that participate in stress
responses such as DNA damage-
induced cell cycle arrest or adaptation to
hypoxia. A number of examples linking
alterations in proteasomal protein degra-
dation to the pathogenesis of cancer
exist (Pagano and Benmaamar, 2003). In
contrast, alterations in autophagic degra-
dation of cellular proteins has not been
linked to the causation of cancer. Rather,
autophagy has been demonstrated to be
important in developmental/differentia-
tive remodeling of cells. Autophagy is
also required for the cellular adaptation
to nutrient deprivation and the elimina-
tion of damaged organelles (Figure 1;
Klionsky and Emr, 2000).
Regulation of autophagy
During autophagic degradation, cytoso-
lic proteins and/or organelles are first
sequestered within double membrane
vesicles, which are then fused to the
lysosome (Klionsky and Emr, 2000). The
vesicular contents are broken down by
pH-sensitive lysosomal hydrolases, and
the degradation products are recycled
for use in macromolecular synthesis
and/or bioenergetics. Relatively little is
known about how protein complexes and
organelles are specifically targeted for
degradation through autophagy.
However, much of the molecular machin-
ery required for autophagic vacuole for-
mation and fusion with the lysosome has
been identified through genetic screens
Defective autophagy leads to cancer
Cellular proteins are degraded within two distinct compartments: the proteasome and the lysosome. Alterations in protea-
somal degradation can contribute to carcinogenesis. In contrast, alterations in autophagic protein degradation through the
lysosome have not been linked to cancer. Now two reports demonstrate that the autophagic gene, Beclin 1, is a haploinsuf-
ficient tumor suppressor gene.These new data suggest that autophagic degradation provides an important mechanism to
prevent cellular transformation.
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to identify proteins necessary for cell sur-
vival when external nutrient supplies are
low. To date, more than 20 genes have-
been identified which are required to
induce autophagy in response to starva-
tion conditions (Klionsky and Emr, 2000).
Recently, it has been demonstrated
that protein turnover by autophagy is dif-
ferentially regulated by type I and type III
PI3 kinases (Ogier-Denis and Codogno,
2003).Type I PI3 kinases and their down-
stream signal transduction components,
Akt and TOR, have been implicated in
suppressing autophagy, while the tumor
suppressor, PTEN, acts as a negative
regulator of the activity of type I PI3
kinases and acts as an activator of
autophagy. In contrast, type III PI3 kinas-
es have been shown to be required for
both autophagic vesicle formation and
vesicular transport to the lysosome.
Beclin 1, a haploinsufficient tumor
suppressor gene that regulates
autophagy
One type III PI3 kinase-interacting pro-
tein that participates in the induction of
autophagy in response to starvation is
Apg6. Recently, the mammalian ortholog
of Apg6, Beclin 1, was found to be
monoallelically deleted in a high percent-
age of ovarian, breast, and prostate can-
cers, and established tumor cell lines
from these tissues express low to unde-
tectable levels of Beclin 1 protein (Liang
et al., 1999). Furthermore, transfection of
Beclin 1 into a transformed breast carci-
noma cell line decreased its tumorigenic
potential in nude mice. To investigate
whether Beclin 1 acts as a tumor sup-
pressor and whether loss of Beclin 1
would contribute to an increased inci-
dence of cancer, two groups have now
generated beclin 1-deficient mice (Qu et
al., 2003; Yue et al., 2003). These mice
demonstrate that Beclin 1 loss is associ-
ated with a reduction in autophagic vac-
uole formation, that Beclin 1-mediated
regulation of autophagy is required for
normal mammalian development, and
that animals with reduced levels of
Beclin 1 display a pronounced increase
in epithelial and hematopoietic malig-
nancies.
Apg6 is not an essential gene in
yeast. Similarly, Yue et al. found that
beclin 1 is not required for ES cell growth
under standard culture conditions.
Furthermore, it does not appear to be
absolutely required for autophagic vac-
uole formation, although loss of beclin 1
suppresses the autophagic response to
nutrient limitation, suggesting that beclin
1 plays a regulatory rather than required
role in autophagy. Despite the fact that
Beclin 1 is not required for cellular sur-
vival, beclin 1-deficient embryos did not
develop past embryonic day 8.5 because
of their inability to undergo remodeling
and proper differentiation of ventral
endoderm (Yue et al., 2003). These
results confirm that autophagy plays a
role in developmental/differentiative tis-
sue remodeling. However, the most sur-
prising result of both studies is that
beclin 1-haploinsufficient animals, as
they age, displayed a pronounced
increase in the incidence of lymphoma
and carcinoma of the lung and liver. In
addition, mammary tissues in these ani-
mals displayed hyperproliferative, pre-
neoplastic changes in reponse to beclin
1 deletion (Qu et al., 2003).
On the surface, the ability of Beclin 1
deficiency to increase tumorigenesis is
counterintuitive. Autophagy is an adap-
tive response to nutrient deprivation,
allowing cells to persist for prolonged
periods under suboptimal nutrient condi-
tions. Cancer cells are frequently sub-
jected to nutrient limitation, as growth of
the tumor frequently outstrips the ability
of the vasculature to supply oxygen and
essential nutrients to maintain macro-
molecular synthesis and bioenergetics.
Therefore, it might have been expected
that an intact autophagic pathway would
be essential for tumor cells to adapt and
survive in vivo. Although it remains pos-
sible that Beclin 1’s role as a tumor sup-
pressor does not reflect its role in
autophagy, there are several potential
mechanisms by which inhibition of
autophagic degradation might contribute
to cellular transformation.
Autophagy as an alternative form of
programmed cell death
Recently, an alternative form of pro-
grammed cell death that occurs indepen-
dently of caspase activation has been
described in neurons (Klionsky and Emr,
2000). This cell death has been termed
type II programmed cell death and is
morphologically associated with massive
induction of autophagic vacuole forma-
tion. Based on this morphologic finding, it
has been suggested that unrestrained
autophagic proteolysis represents an
alternative pathway for programmed cell
death and thus limits cell-autonomous
survival. The fact that neither Qu et al. or
Yue et al. found any protection from pro-
grammed cell death in cells deficient in
beclin 1 argues against this explanation
for increased tumor formation in Beclin
1-deficient mice. A more definitive test of
this hypothesis is likely to be forthcom-
ing. Although Yue et al. produced beclin
1-deficient ES and demonstrated that
they exhibit a pronounced reduction in
autophagic vesicle formation in response
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Figure 1. Beclin 1 is required for a proximal step in autophagy
Autophagy consists of five basic steps: (1) in addition to constitutive, housekeeping degrada-
tive functions, autophagy is induced by nutrient limitation or to remove damaged or excess
organelles; (2) a double membrane bound autophagosome forms enclosing organelles, pro-
teins, and cytosol; (3) the autophagosome is trafficked to the lysosome; (4) the autophago-
some fuses with the lysosome; and (5) the contents of the autophagosome are degraded.
Beclin 1 appears to be involved in the formation of the autophagosome and thus blocks
autophagy at an early step.
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to nutrient deprivation, the group did not
evaluate whether this reduction in
autophagy was associated with
enhanced cellular survival. It will be
important to determine whether the inhi-
bition of autophagy associated with
Beclin 1 deficiency increases cellular
survival as would be predicted if
autophagy is the mediator of type II pro-
grammed cell death, or whether inhibi-
tion of autophagy decreases cell survival
in response to conditions of cellular
stress or nutrient deprivation as would
be predicted from comparable studies in
yeast.
Autophagy as a mechanism to
decrease genotoxic stress
Autophagy plays a critical role in remov-
ing damaged or surplus organelles in
order to maintain cellular homeostasis.
For example, by removing damaged
mitochondria, autophagy may limit the
exposure of cellular DNA to genotoxic
stresses such as free radicals. The
removal of damaged mitochondria
through autophagic degradation would
thus decrease the basal mutation rate
and suppress oncogenesis.This model is
consistent with the speculation that the
levels of endogenous cellular oxidants
produced during normal physiology or in
response to extrinsic damage may be the
major contributors to the basal mutation
rate observed in cells (Ames et al., 1995).
Thus, removal of sources of oxidant
stress such as damaged mitochondria or
endoplasmic reticulum by autophagy
might limit genotoxic damage.
Beclin 1 as a regulator of selective
turnover of proteins involved in cell
growth and proliferation
As mentioned above, Beclin 1 is not
required for autophagic degradation but
instead appears to play a more special-
ized role, possibly regulating the magni-
tude of the autophagic response or
restricting degradation to proteins from
specific cellular compartments or to spe-
cific cellular conditions. For example,
Beclin 1 could be involved in the turnover
of proteins required for the positive regu-
lation of cell growth and proliferation.
Evidence that Beclin 1 can play a
specific role in protein degradation is
demonstrated by the fact that the overex-
pression of the Beclin 1 binding protein,
CAL (also known as PIST), decreases
the cell surface expression of the CFTR
chloride channel, while levels of P glyco-
protein were unaffected (Cheng et al.,
2002). Thus, a Beclin 1-containing pro-
tein complex may regulate the trafficking
and turnover of other plasma membrane
proteins that are involved in signal trans-
duction and/or nutrient acquisition.
Consistent with this possibility, another
gene involved in the regulation of
autophagy, the small GTPase Rab7, has
recently been implicated in the degrada-
tion of nutrient transporters in response
to growth factor withdrawal (Edinger et
al., 2003). Under these conditions, Rab7
deficiency leads to prolonged cell-
autonomous survival in the absence of
growth factors. Loss of Rab7 also pro-
moted in vitro cellular transformation by
E1A. Together, the data suggests that
when the expression of growth-promot-
ing proteins is uncoupled from the signal
transduction events that initiate or pro-
mote their activities, the enhanced/pro-
longed expression of such proteins may
contribute to cellular transformation.
Consistent with this possibility, enhance-
ment of cellular translation through
upregulation of the limiting translation
factor, eIF4E, was demonstrated to pro-
mote transformation (Sonenberg and
Gingras, 1998).The ability of eIF4E over-
expression to promote transformation is
consistent with the above model, illus-
trating the “flip side” of the coin. eIF4E is
the limiting factor for the translation of
growth-promoting mRNAs. Enhanced
expression of eIF4E appears to override
the ability of cells to turn off a growth-
promoting cellular program, and thus
eIF4E acts as an oncogene to maintain
cell growth and proliferation.
Conclusions
Like many important initial observations,
the increased tumor incidence associat-
ed with the loss of the ability to properly
regulate autophagy appears to raise
more questions than it answers. It seems
likely that a more precise understanding
of the cellular role of Beclin 1 may pro-
vide important insights into how regula-
tion of protein turnover through
autophagy contributes to cellular home-
ostasis. Further elucidating the molecu-
lar basis for the regulation of autophagy
by Beclin 1 is also likely to shed light on
the mechanism by which Beclin 1 sup-
presses tumor formation.
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